SCHEDULE: Armistice Capital Boosts Supernus Stake to 8.58%

Armistice Capital, LLC and Steven Boyd reported beneficial ownership of 8.58% of Supernus Pharmaceuticals, Inc. common stock, totaling 4,812,000 shares.

Summary

• Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 4,812,000 shares of Supernus Pharmaceuticals, Inc. common stock.
• This represents 8.58% of the company's outstanding common stock.
• The percentage is calculated based on 56,073,088 shares outstanding as of July 29, 2025, as reported in the Issuer's Form 10-Q filed on August 5, 2025.
• Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these securities.
• Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these shares.
• This filing is an Amendment No. 8 to a previously filed Schedule 13G.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a significant beneficial ownership stake by an institutional investor. While not directly positive or negative about the company's performance, the continued substantial holding by Armistice Capital can be seen as a neutral to slightly positive signal of institutional confidence or strategic interest.

Positives

• A significant institutional investor, Armistice Capital, maintains a substantial stake (8.58%) in Supernus Pharmaceuticals, Inc., indicating continued interest.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Risks

• No specific risks related to the company's operations or financial health are disclosed in this ownership filing. The filing explicitly states the shares were not acquired for the purpose of changing or influencing control.

Future Outlook

Not applicable as this filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer.

Industry Context

This filing indicates continued institutional investment interest in the pharmaceutical sector, specifically in Supernus Pharmaceuticals, Inc. The maintenance of a significant stake by Armistice Capital suggests a long-term view or strategic position within the industry.

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional stake provides transparency regarding the ownership structure and may influence investor perception.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses a significant beneficial ownership stake by Armistice Capital, LLC and Steven Boyd in Supernus Pharmaceuticals, Inc. While the maintenance of an 8.58% stake by a notable institutional investor indicates continued interest, this filing alone does not provide sufficient operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It is a transparency filing, not a performance report. Investors should 'hold' and await further financial disclosures (e.g., 10-Q, 10-K) to assess the company's fundamentals and future prospects before making a definitive investment decision.

Keywords

Supernus Pharmaceuticals, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Institutional Investor, Pharmaceuticals, Common Stock